Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interaction of BMS-986322 and Loestrin in Healthy Females
NCT05579574Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lomedeucitinib in psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration (Cmax) for EE/NET up to 28 days, Cmax for EE/NET with BMS-986322 up to 28 days and 2 more. Started Oct 2022; status: completed.
02
Drugs
lomedeucitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05579574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579574.